{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:27:14Z","timestamp":1757312834596},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s10147-011-0369-1","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T05:08:53Z","timestamp":1326258533000},"page":"40-47","source":"Crossref","is-referenced-by-count":22,"title":["Pathological and molecular biological approaches to early mesothelioma"],"prefix":"10.1007","volume":"17","author":[{"given":"Tohru","family":"Tsujimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Torii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayuko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misa","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"369_CR1","doi-asserted-by":"crossref","DOI":"10.3109\/9780203994474","volume-title":"Mesothelioma","author":"BWS Robinson","year":"2002","unstructured":"Robinson BWS, Chahinian AP (2002) Mesothelioma. Martin Dunitz Ltd, London"},{"key":"369_CR2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","volume":"353","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353:1591\u20131603","journal-title":"N Engl J Med"},{"key":"369_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30227","volume":"29","author":"M Carbone","year":"2002","unstructured":"Carbone M, Kratzke RA, Testa JR (2002) The pathogenesis of mesothelioma. Semin Oncol 29:2\u201317","journal-title":"Semin Oncol"},{"key":"369_CR4","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao AS, Wistuba I, Roth JA et al (2009) Malignant pleural mesothelioma. J Clin Oncol 27:2081\u20132090","journal-title":"J Clin Oncol"},{"key":"369_CR5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2559.2008.03178.x","volume":"54","author":"B Addis","year":"2009","unstructured":"Addis B, Roche H (2009) Problems in mesothelioma diagnosis. Histopathology 54:55\u201368","journal-title":"Histopathology"},{"key":"369_CR6","volume-title":"World Health Organization classification of tumours, pathology and genetics of tumours of the lung, pleura, thymus and heart","author":"WD Travis","year":"2004","unstructured":"Travis WD, Brambilla E, Muller-Hermelink HK et al (2004) World Health Organization classification of tumours, pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon"},{"key":"369_CR7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0003-4975(92)90654-M","volume":"54","author":"DJ Sugarbaker","year":"1992","unstructured":"Sugarbaker DJ, Mentzer SJ, Strauss G (1992) Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Thorac Surg 54:941\u2013946","journal-title":"Ann Thorac Surg"},{"key":"369_CR8","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/00000478-200009000-00001","volume":"24","author":"A Churg","year":"2000","unstructured":"Churg A, Colby TV, Cagle P et al (2000) The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24:1183\u20131200","journal-title":"Am J Surg Pathol"},{"key":"369_CR9","first-page":"83","volume-title":"AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3","author":"A Churg","year":"2006","unstructured":"Churg A, Cagle PT, Roggli VL (2006) Separation of benign and malignant mesothelial proliferations. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 83\u2013101"},{"key":"369_CR10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/dc.2840080405","volume":"8","author":"MW Stevens","year":"1992","unstructured":"Stevens MW, Leong AS, Fazzalari NL et al (1992) Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol 8:333\u2013341","journal-title":"Diagn Cytopathol"},{"key":"369_CR11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1365-2303.2000.00247.x","volume":"11","author":"D Whitaker","year":"2000","unstructured":"Whitaker D (2000) The cytology of malignant mesothelioma. Cytopathology 11:139\u2013151","journal-title":"Cytopathology"},{"key":"369_CR12","first-page":"11","volume-title":"AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3","author":"A Churg","year":"2006","unstructured":"Churg A, Cagle PT, Roggli VL (2006) Cytology of the serosal surfaces. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 11\u201331"},{"key":"369_CR13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/dc.20938","volume":"37","author":"E Cakir","year":"2009","unstructured":"Cakir E, Demirag F, Aydin M et al (2009) Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: a logistic regression analysis. Diagn Cytopathol 37:4\u201310","journal-title":"Diagn Cytopathol"},{"key":"369_CR14","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/dc.21128","volume":"37","author":"N Kimura","year":"2009","unstructured":"Kimura N, Data K, Araya Y et al (2009) Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens. Diagn Cytopathol 37:885\u2013890","journal-title":"Diagn Cytopathol"},{"key":"369_CR15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/modpathol.3800732","volume":"20","author":"Y Kato","year":"2007","unstructured":"Kato Y, Tsuta K, Seki K et al (2007) Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 20:215\u2013220","journal-title":"Mod Pathol"},{"key":"369_CR16","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/modpathol.2010.134","volume":"23","author":"A Sato","year":"2010","unstructured":"Sato A, Torii I, Okamura Y et al (2010) Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol 23:1458\u20131466","journal-title":"Mod Pathol"},{"key":"369_CR17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1309\/AJCPWFW7O1FVFLKT","volume":"131","author":"J Shen","year":"2009","unstructured":"Shen J, Pinkus GS, Deshpande V et al (2009) Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol 131:516\u2013523","journal-title":"Am J Clin Pathol"},{"key":"369_CR18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/PAS.0b013e318218985b","volume":"35","author":"M Shi","year":"2011","unstructured":"Shi M, Fraire AE, Chu P et al (2011) Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol 35:878\u2013882","journal-title":"Am J Surg Pathol"},{"key":"369_CR19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/bjc.2011.104","volume":"104","author":"S Bij van der","year":"2011","unstructured":"van der Bij S, Schaake E, Koffijberg H et al (2011) Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 104:1325\u20131333","journal-title":"Br J Cancer"},{"key":"369_CR20","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.5858\/2005-129-1421-DDOBAM","volume":"129","author":"PT Cagle","year":"2005","unstructured":"Cagle PT, Churg A (2005) Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 129:1421\u20131427","journal-title":"Arch Pathol Lab Med"},{"key":"369_CR21","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/133.8.1317","volume":"133","author":"AN Husain","year":"2009","unstructured":"Husain AN, Colby TV, Ordonez NG et al (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 133:1317\u20131331","journal-title":"Arch Pathol Lab Med"},{"key":"369_CR22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-642-10862-4_10","volume":"189","author":"S Klebe","year":"2011","unstructured":"Klebe S, Henderson DW (2011) Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res 189:169\u2013193","journal-title":"Recent Results Cancer Res"},{"key":"369_CR23","first-page":"151","volume":"9","author":"D Whitaker","year":"1992","unstructured":"Whitaker D, Henderson DW, Shilkin KB (1992) The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 9:151\u2013161","journal-title":"Semin Diagn Pathol"},{"key":"369_CR24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ajcp\/110.3.397","volume":"110","author":"DW Henderson","year":"1998","unstructured":"Henderson DW, Shilkin KB, Whitaker D (1998) Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 110:397\u2013404","journal-title":"Am J Clin Pathol"},{"key":"369_CR25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/978-0-387-72114-9_12","volume-title":"Dail and Hammar\u2019s pulmonary pathology, chap 43, vol 2","author":"SP Hammar","year":"2008","unstructured":"Hammar SP, Henderson DW, Klebe S et al (2008) Neoplasms of the pleura. In: Tomashefski JFJ (ed) Dail and Hammar\u2019s pulmonary pathology, chap 43, vol 2, 3rd edn. Springer, New York, pp 558\u2013734","edition":"3"},{"key":"369_CR26","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","volume":"108","author":"VW Rusch","year":"1995","unstructured":"Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122\u20131128","journal-title":"Chest"},{"key":"369_CR27","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1378\/chest.111.6.1710","volume":"111","author":"CF Mountain","year":"1997","unstructured":"Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710\u20131717","journal-title":"Chest"},{"key":"369_CR28","unstructured":"Kamei T (2010) Cytological diagnosis for mesothelioma. In: An abstract of the 10th international conference of the international mesothelioma interest group, Aug 31\u2013Sept 3, 2010 Kyoto, Japan, p\u00a036"},{"key":"369_CR29","first-page":"33","volume-title":"AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3","author":"A Churg","year":"2006","unstructured":"Churg A, Cagle PT, Roggli VL (2006) Diffuse malignant tumors of the serosal membranes. In: Silverberg SG, Sobin LH (eds) AFIP Atlas of tumor pathology: tumors of the serosal membranes. 4th series, fascicle 3. American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology, Washington, pp 33\u201382"},{"key":"369_CR30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.9044","volume":"93","author":"PA Fetsch","year":"2001","unstructured":"Fetsch PA, Abati A (2001) Immunocytochemistry in effusion cytology: a contemporary review. Cancer 93:293\u2013308","journal-title":"Cancer"},{"key":"369_CR31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/dc.20747","volume":"36","author":"RT Pu","year":"2008","unstructured":"Pu RT, Pang Y, Michael CW (2008) Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5\/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol 36:20\u201325","journal-title":"Diagn Cytopathol"},{"key":"369_CR32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2009.06.014","volume":"41","author":"JA Bishop","year":"2010","unstructured":"Bishop JA, Sharma R, Illei PB (2010) Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, and malignant mesothelioma. Hum Pathol 41:20\u201325","journal-title":"Hum Pathol"},{"key":"369_CR33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0046-8177(99)90096-5","volume":"30","author":"A Khoor","year":"1999","unstructured":"Khoor A, Whitsett JA, Stahlman MT et al (1999) Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 30:695\u2013700","journal-title":"Hum Pathol"},{"key":"369_CR34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<583::AID-CNCR22>3.0.CO;2-X","volume":"82","author":"KD Wolanski","year":"1998","unstructured":"Wolanski KD, Whitaker D, Shilkin KB et al (1998) The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 82:583\u2013590","journal-title":"Cancer"},{"key":"369_CR35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/dc.20208","volume":"32","author":"RS Saad","year":"2005","unstructured":"Saad RS, Cho P, Liu YL (2005) The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 32:156\u2013159","journal-title":"Diagn Cytopathol"},{"key":"369_CR36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-2559.2003.01686.x","volume":"43","author":"RL Attanoos","year":"2003","unstructured":"Attanoos RL, Griffin A, Gibbs AR (2003) The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43:231\u2013238","journal-title":"Histopathology"},{"key":"369_CR37","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/path.1711680406","volume":"168","author":"M Ramael","year":"1992","unstructured":"Ramael M, Lemmens G, Eerdekens C et al (1992) Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 168:371\u2013375","journal-title":"J Pathol"},{"key":"369_CR38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0046-8177(94)90243-7","volume":"25","author":"J Hurlimann","year":"1994","unstructured":"Hurlimann J (1994) Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol 25:753\u2013757","journal-title":"Hum Pathol"},{"key":"369_CR39","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/00000478-200111000-00008","volume":"25","author":"B Davidson","year":"2001","unstructured":"Davidson B, Nielsen S, Christensen J et al (2001) The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25:1405\u20131412","journal-title":"Am J Surg Pathol"},{"key":"369_CR40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO;2-F","volume":"189","author":"PM Cury","year":"1999","unstructured":"Cury PM, Butcher DN, Corrin B et al (1999) The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 189:251\u2013257","journal-title":"J Pathol"},{"key":"369_CR41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2559.2006.02442.x","volume":"49","author":"J King","year":"2006","unstructured":"King J, Thatcher N, Pickering C et al (2006) Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 49:561\u2013568","journal-title":"Histopathology"},{"key":"369_CR42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00000478-200203000-00011","volume":"26","author":"F Kumaki","year":"2002","unstructured":"Kumaki F, Kawai T, Churg A et al (2002) Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 26:365\u2013370","journal-title":"Am J Surg Pathol"},{"key":"369_CR43","first-page":"511","volume":"11","author":"S Xio","year":"1995","unstructured":"Xio S, Li D, Vijg J et al (1995) Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11:511\u2013515","journal-title":"Oncogene"},{"key":"369_CR44","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<649::AID-IJC25>3.0.CO;2-2","volume":"75","author":"JB Prins","year":"1998","unstructured":"Prins JB, Williamson KA, Kamp MM et al (1998) The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75:649\u2013653","journal-title":"Int J Cancer"},{"key":"369_CR45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/cncr.23413","volume":"114","author":"FB Onofre","year":"2008","unstructured":"Onofre FB, Onofre AS, Pomjanski N et al (2008) 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 114:204\u2013215","journal-title":"Cancer"},{"key":"369_CR46","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1440-1827.2010.02534.x","volume":"60","author":"M Takeda","year":"2010","unstructured":"Takeda M, Kasai T, Enomoto Y et al (2010) 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int 60:395\u2013399","journal-title":"Pathol Int"},{"key":"369_CR47","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jcp.2010.076794","volume":"63","author":"CT Chung","year":"2010","unstructured":"Chung CT, Santos Gda C, Hwang DM et al (2010) FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 63:630\u2013634","journal-title":"J Clin Pathol"},{"key":"369_CR48","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1309\/AJCPP5R2ZJZKCLWN","volume":"135","author":"SE Monaco","year":"2011","unstructured":"Monaco SE, Shuai Y, Bansal M et al (2011) The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 135:619\u2013627","journal-title":"Am J Clin Pathol"},{"key":"369_CR49","doi-asserted-by":"crossref","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","volume":"6","author":"DA Altomare","year":"2011","unstructured":"Altomare DA, Menges CW, Xu J et al (2011) Losses of both products of the Cdkn2a\/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PloS One 6:e18828","journal-title":"PloS One"},{"key":"369_CR50","first-page":"1227","volume":"55","author":"Y Sekido","year":"1995","unstructured":"Sekido Y, Pass HI, Bader S et al (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227\u20131231","journal-title":"Cancer Res"},{"key":"369_CR51","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","volume":"92","author":"AB Bianchi","year":"1995","unstructured":"Bianchi AB, Mitsunaga SI, Cheng JQ et al (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854\u201310858","journal-title":"Proc Natl Acad Sci USA"},{"key":"369_CR52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/humu.20317","volume":"27","author":"ME Baser","year":"2006","unstructured":"Baser ME (2006) The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 27:297\u2013306","journal-title":"Hum Mutat"},{"key":"369_CR53","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1101\/gad.1335605","volume":"19","author":"AI McClatchey","year":"2005","unstructured":"McClatchey AI, Giovannini M (2005) Membrane organization and tumorigenesis\u2014the NF2 tumor suppressor, Merlin. Genes Dev 19:2265\u20132277","journal-title":"Genes Dev"},{"key":"369_CR54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami H, Mizuno T, Taniguchi T et al (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71:873\u2013883","journal-title":"Cancer Res"},{"key":"369_CR55","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1158\/0008-5472.CAN-05-2312","volume":"65","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, Vaslet CA, Skele KL et al (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65:8090\u20138095","journal-title":"Cancer Res"},{"key":"369_CR56","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","volume":"16","author":"DE Jensen","year":"1998","unstructured":"Jensen DE, Proctor M, Marquis ST et al (1998) BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16:1097\u20131112","journal-title":"Oncogene"},{"key":"369_CR57","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","volume":"69","author":"H Nishikawa","year":"2009","unstructured":"Nishikawa H, Wu W, Koike A et al (2009) BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity. Cancer Res 69:111\u2013119","journal-title":"Cancer Res"},{"key":"369_CR58","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson ED et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410\u20131413","journal-title":"Science"},{"key":"369_CR59","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668\u2013672","journal-title":"Nat Genet"},{"key":"369_CR60","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022\u20131025","journal-title":"Nat Genet"},{"key":"369_CR61","first-page":"1365","volume":"39","author":"Y Yoshikawa","year":"2011","unstructured":"Yoshikawa Y, Sato A, Tsujimura T et al (2011) Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol 39:1365\u20131374","journal-title":"Int J Oncol"},{"key":"369_CR62","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","volume":"98","author":"T Taniguchi","year":"2007","unstructured":"Taniguchi T, Karnan S, Fukui T et al (2007) Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98:438\u2013446","journal-title":"Cancer Sci"},{"key":"369_CR63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","volume":"51","author":"A Destro","year":"2006","unstructured":"Destro A, Ceresoli GL, Falleni M et al (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51:207\u2013215","journal-title":"Lung Cancer"},{"key":"369_CR64","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, You H, Xiao GH et al (2005) Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24:6080\u20136089","journal-title":"Oncogene"},{"key":"369_CR65","first-page":"181","volume":"2","author":"Y Suzuki","year":"2009","unstructured":"Suzuki Y, Murakami H, Kawaguchi K et al (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2:181\u2013188","journal-title":"Mol Med Rep"},{"key":"369_CR66","first-page":"1375","volume":"8","author":"T Papp","year":"2001","unstructured":"Papp T, Schipper H, Pemsel H et al (2001) Mutational analysis of the PTEN\/MMAC1 tumour suppressor gene in primary human malignant mesotheliomas. Oncol Rep 8:1375\u20131379","journal-title":"Oncol Rep"},{"key":"369_CR67","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/jnci\/87.24.1870","volume":"87","author":"RA Kratzke","year":"1995","unstructured":"Kratzke RA, Otterson GA, Lincoln CE et al (1995) Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87:1870\u20131875","journal-title":"J Natl Cancer Inst"},{"key":"369_CR68","first-page":"425","volume":"18","author":"T Papp","year":"2001","unstructured":"Papp T, Schipper H, Pemsel H et al (2001) Mutational analysis of N-ras, p53, p16 INK4a , p14 ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18:425\u2013433","journal-title":"Int J Oncol"},{"key":"369_CR69","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/ng1975","volume":"39","author":"RK Thomas","year":"2007","unstructured":"Thomas RK, Baker AC, Debiasi RM et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347\u2013351","journal-title":"Nat Genet"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0369-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-011-0369-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0369-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T18:55:49Z","timestamp":1640458549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-011-0369-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1007\/s10147-011-0369-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,12]]}}}